Citations

Showing 10 of 108152 citations.

Abstract P332: Thirty Day Readmissions After Myocardial Infarction in the Community
Weston, Susan A., Killian, Jill M. , Bell, Malcolm R. , Jaffe, Allan S. , Roger, Véronique L. , Dunlay, Shannon M. , Jaffe, Allan S.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.ap332 Get It

Background: Hospital readmissions are considered to be a quality of care indicator, yet little is known about their occurrence and predictors after myocardial infarction (MI) in the community. Methods: We identified all Olmsted County residents with incident MI from 1987-2007 and evaluated 30-day rehospitalizations. The reason for readmission was categorized based on ICD-9 code. Safety endpoints of revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or fibrinolysis included stroke, acute kidney injury (rise in creatinine post-procedure of >0.5 mg/dL), access site complication (PCI), and gastrointestinal or other bleeding. Cox proportional hazard regression models were used to examine the predictors of readmission. Results: A total of 2617 patients (mean age 67 years, 41% female) had incident MI (32% with ST-elevation) from 1987-2007 and survived their initial hospitalization. A total of 583 readmissions occurred within 30 days among 512 (19.6%) patients. Approximately half (n=286, 49.1%) of readmissions were due to cardiovascular causes, and of these, most were due to ischemic heart disease (n=175, 61.2%) or heart failure (n=56, 19.6%). The proportion of non-cardiovascular rehospitalizations increased over time, from 42.2% from 1993-97 to 59.4% from 2003-07 (p for trend=0.01). A minority of those readmitted for cardiovascular reasons required repeat angiogram (n=110, 38.5%) or revascularization (n=88, 50 PCI, 38 CABG). After adjustment for confounders, key factors were associated with increased rehospitalization risk ( Figure ). Following PCI (n=1230), a stroke or bleeding event (adjusted HR 1.69, 95% CI 1.09-2.61, p=0.02) and acute kidney injury (HR 2.50, 95% CI 1.61-3.87, p<0.01) were associated with markedly increased readmission risk. Conclusions: Half of readmissions within 30 days of MI are for non-cardiovascular reasons, and this proportion has increased. Comorbidity and complications of revascularization are key predictors of readmission.
Abstract P246: Heart Failure Performance Measures: Eligibility and Implementation In the Community
Redfield, Margaret M. , McNallan, Sheila M, Weston, Susan A., Jiang, Ruoxiang , Roger, Véronique L. , Berardi, Cecilia , Chamberlain, Alanna M. , Bursi, Francesca

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.ap246 Get It

Background: The goal of heart failure (HF) performance measures is to improve the quality of care by enabling the practice implementation of guidelines. The guidelines define the population eligible for each measure. Little is known about the proportion of eligible patients to which these measures are applicable in the community. Methods: We determined the eligibility for and the adherence to performance measures and beta-blocker therapy in a community-based cohort of hospitalized patients diagnosed with incident HF from January 2005 to April 2011. Results: Of 294 inpatients with first ever HF (mean age 72 ± 15 years, 48% men), ejection fraction was measured in 292 (99%) patients during hospitalization. Of these, 97 (33%) had an ejection fraction <40% and were thus candidates for beta-blocker and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB) therapy. After excluding individuals with absolute contraindications, 71 patients were eligible to receive ACE inhibitors or ARB, and 86 were eligible to receive beta-blockers (figure). Among those eligible, 83% received ACEI/ARB and 91% received beta-blockers. Excluding those with relative contraindications, 70 patients were eligible for beta-blockers and 90% of them received it. Among the 139 (47%) individuals with HF and atrial fibrillation, 35 were eligible for warfarin and 49% received it. Of the 36 current smokers, 22 (61%) received cessation counseling during hospitalization. Conclusions: In the community, among patients hospitalized with HF eligible for performance measures, the implementation of performance measures varies by measure and can be improved for some. However, most community HF patients are not eligible for performance measures and other approaches should be identified to improve their care and outcomes.
Abstract P242: Measuring Frailty in Heart Failure: A Community Perspective
McNallan, Sheila M, Weston, Susan A., Jiang, Ruoxiang , Roger, Véronique L. , Chamberlain, Alanna M. , Gerber, Yariv , Singh, Mandeep

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.ap242 Get It

Objective: To compare two measures of frailty in a community cohort of heart failure (HF) patients. Background: Frailty is increasingly recognized as an important prognostic indicator in HF. Several methods have been proposed to measure frailty. Some conceptualize frailty as a biological phenotype, while others define it as an accumulation of deficits (impairments, disabilities, comorbid diseases), termed the Cumulative Deficit Index (CDI). Each approach has conceptual strengths and limitations; a distinct feature of the CDI is the ability to extract data from medical records. These two methods have never been compared in a community HF cohort. Methods: Olmsted, Dodge and Fillmore County, MN residents with HF between 10/2007 and 12/2010 were prospectively recruited to assess the frailty phenotype. The biological frailty phenotype was defined as ≥3 of the following: unintentional weight loss >10 lbs. in 1 year, physical exhaustion, weak grip strength, and slowness and low activity measured by the SF-12 physical component score. Intermediate frailty was defined as having 1–2 components. The CDI was based on 33 deficits and defined as the proportion of deficits present for each patient. Results: Among 131 patients (mean age 70.5±14, 62% male), according to the biological frailty phenotype definition 18% were frail, 50% intermediate frail and 31% not frail. The CDI ranged from 0.03–0.70, with a mean (SD) of 0.22 (0.12). The CDI was significantly correlated with the frailty phenotype (r=0.59, p<0.001). The mean (SD) of the CDI was 0.35 (0.14), 0.21 (0.10) and 0.15 (0.07) among the frail, intermediate frail and not frail phenotypes (Figure). Conclusion: The CDI is significantly associated with the biological frailty phenotype and can thus be used as an alternative approach to measure frailty in HF. As the components of the biological frailty phenotype are not routinely assessed clinically, the CDI, which can be ascertained from medical records, is a feasible approach to ascertain frailty in large cohorts.
Abstract P240: End of Life Costs in Community Patients with Heart Failure
Shah, Nilay D. , VanHouten, Holly, Roger, Véronique L. , Dunlay, Shannon M.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.ap240 Get It

Background: Heart failure (HF) care constitutes an increasing economic burden on the healthcare system, and has become a key focus in the healthcare debate. Costs incurred at the end of life can be particularly high in some populations, however, end of life costs among a community population of HF patients have not been well delineated. Methods: Olmsted County residents with incident HF from 1987-2006 were identified and followed until death. Direct medical costs incurred in the last 6 months prior to death were obtained using population-based administrative data through 2010. For those that died within 6 months of HF diagnosis, costs were included from diagnosis until death. Costs were inflated to 2010 U.S. dollars using the general Consumer Price Index (CPI). Results: A total of 862 HF patients were identified, died during follow-up, and had complete cost data (mean age 79.4 years, 46.4% male, 56.5% EF≥50%). Median costs within the last 6 months of life were $12,069 per person (25 th -75 th percentile $1768 - $30,841, mean $24,052), with the majority accumulated during hospitalizations (median $8849 per person, mean $20,263, 84.2% total costs for population). A total of 596 (69.1%) patients were hospitalized in the last 6 months of life, and 235 (27.3%) died in the hospital. Costs progressively increased in the months prior to death (Figure), with nearly half (43.4%) of total costs in the last 6 months of life accumulated during the month before death. End of life costs did not change over the study period (p=0.154 adjusted for age and sex). Conclusions: End of life costs are high among community HF patients, particularly in the final month of life. Most of these costs are accumulated during hospitalizations, and a large proportion of HF patients died in the hospital. Among patients with HF nearing the end of life, alternative strategies of care that avoid hospitalizations may be particularly cost-saving.
Abstract P113: New-onset Atrial Fibrillation and Risk of Mortality and Cardiovascular Disease in Whites and African Americans: the ARIC Study
Agarwal, Sunil , Lopez, Faye L., Loehr, Laura R, Alonso, Álvaro , Soliman, Elsayed Z. , Chen, Lin Y. , Chamberlain, Alanna M. , Loehr, Laura R

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.ap113 Get It

Background: Multiple studies have shown that atrial fibrillation (AF), a common cardiac arrhythmia, is associated with increased mortality and higher incidence of stroke and heart failure. However, evidence for this association in African Americans is lacking. Methods: We studied 4,063 African Americans and 11,280 whites in the Atherosclerosis Risk in Communities (ARIC) Study, a US community-based cohort study, aged 45-64 (55% women) and free of AF at baseline in 1987-89. Three additional follow-up exams were conducted in 1990-92, 1993-95, and 1996-98. AF was ascertained during follow-up with study visit ECGs and hospital surveillance. Mortality and incidence of stroke and heart failure were ascertained according to study protocols. Using multivariable Cox proportional hazards models with time-dependent covariates, we calculated hazard ratios (HR) and 95% confidence intervals (CI) of mortality, stroke and heart failure in those with new-onset AF compared to those without AF by race. Results: During an average follow-up of 18 years, 332 AF cases were ascertained in African Americans and 1407 in whites. Overall, African Americans showed higher all-cause mortality and cardiovascular disease rates than whites ( Table ). AF was associated with increased mortality and risk of incident stroke and heart failure in whites and African Americans, even after adjustment for baseline and time-dependent potential confounders ( Table ). Associations of AF with all-cause mortality and stroke were of similar magnitude in both racial groups. However, the association between AF and heart failure was stronger in whites than in African Americans (HR 3.6, 95% CI 3.1-4.2 in whites, vs. HR 2.2, 95% CI 1.6-3.0 in African Americans). Conclusion: New-onset AF was associated with an increased risk of all-cause mortality, stroke, and heart failure in whites and African Americans independently of other cardiovascular risk factors. Table. Hazard ratios (95% confidence interval) of all-cause mortality, stroke, and heart failure in those with new-onset atrial fibrillation (AF) versus those without AF by race, ARIC, 1987-2008 Blacks Whites P for interaction No AF (n=3731) AF (n=332) No AF (n=9873) AF (n=1407) Mortality Deaths (n) 1144 188 2042 630 Person-years 69,483 1268 200,878 7493 Mortality rate 1 18.6 126.3 10.1 62.3 Model 1 1 (ref.) 5.80 (4.93-6.82) 1 (ref.) 4.58 (4.17-5.04) 0.27 Model 2 1 (ref.) 3.20 (2.71-3.76) 1 (ref.) 2.87 (2.61-3.17) 0.68 Stroke Events (n) 281 23 347 64 Person-years 51,082 867 147,608 5040 Incidence rate 1 6.0 25.0 2.4 11.5 Model 1 1 (ref.) 2.91 (1.81-4.68) 1 (ref.) 2.52 (1.86-3.43) 0.94 Model 2 1 (ref.) 1.83 (1.13-2.96) 1 (ref.) 1.91 (1.39-2.62) 0.82 Heart failure Events 613 71 992 364 Person-years 62,570 721 187,847 4578 Incidence rate 1 10.7 108.1 5.3 76.1 Model 1 1 (ref.) 3.35 (2.41-4.65) 1 (ref.) 4.75 (4.09-5.51) 0.02 Model 2 1 (ref.) 2.18 (1.56-3.04) 1 (ref.) 3.63 (3.12-4.21) 0.0006 1 Age- and sex-standardized, per 1000 person-years; Model 1 : Cox proportional hazards model adjusted for age, sex, and study center, with AF incidence as a time-dependent covariate; Model 2 : As model 1, but additionally adjusting for baseline education, and time-dependent body mass index, smoking, diabetes, hypertension, stroke, heart failure, and myocardial infarction Funding(This research has received full or partial funding support from the American Heart Association, National Center)
Abstract P007: Circulating Levels of Soluble P-selectin and Subclinical and Clinical Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)
Sale, Michèle M. , Sicotte, Hugues , Hanson, Naomi Q., Decker, Paul A. , Kirsch, Phillip S., Polak, Joseph, Bielinski, Suzette J. , Pankow, James S. , Tsai, Michael Y. , Andrade, Mariza de , Tang, Weihong , Decker, Paul A.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.ap007 Get It

P-selectin is a cellular adhesion molecule that enhances procoagulant activity and activation of leukocyte integrins. P-selectin has been shown to be crucial in the development of atherosclerosis. Using a stratified random sample of 2406 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) at Exam 2, we investigated the association of soluble P-selectin and cardiovascular disease. The Tobit model was used to investigate the association of P-selectin levels and coronary artery calcium (CAC) and Cox proportional hazards regression was used to assess the association between protein level and incident cardiovascular disease (CVD) events (myocardial infarction, stroke, angina, or other atherosclerotic death). Mean levels of soluble P-selectin differed significantly by ethnicity; 46±18 ng/mL African Americans, 58±20 ng/mL Caucasians, 43±15 ng/mL Chinese, and 61±20 ng/mL Hispanics (p<0.0001). CAC was present in 46% of African Americans, 61% of Caucasians, 52% of Chinese, and 53% of Hispanics. P-selectin levels were significantly associated with CAC in Caucasians (p < 0.001) and African Americans (p = 0.025), see Table. This association was robust to adjustment for traditional risk factors and a significant interaction of P-selectin and ethnicity was observed (p= 0.02). Over an average of 6.5 years of follow-up there were 111 incident CVD events after MESA exam 2, 26 in African Americans, 33 in Caucasians, 16 in Chinese, and 36 in Hispanics. The risk of CVD events increased 34% per standard deviation increase in P-selectin levels only in Caucasians (p = 0.007) and this finding was consistent after adjustment for CVD risk factors (HR = 1.30, p = 0.017). We have shown in this large cohort that mean circulating P-selectin levels differed by ethnicity. Despite similar percentages of subjects with CAC in each ethnic group, P-selectin levels were significantly associated with CAC only in African Americans and Caucasians. Furthermore, in Caucasians only, P-selectin levels were associated with incident CVD events. Association of P-selectin, per SD (20 ng/mL) for the population and cardiovascular disease Outcome African Americans n = 579 Caucasians n = 620 Chinese n = 602 Hispanics n = 605 CAC, Agatston Score Beta (S.E.) P-value Beta (S.E.) P-value Beta (S.E.) P-value Beta (S.E.) P-value Model 1 85.9 (38.4) 0.025 99.4 (28.7) <0.001 8.2 (33.3) 0.81 32.1 (27.3) 0.24 Model 2 79.3 (39.8) 0.046 94.7 (29.1) 0.001 −19.5 (33.6) 0.56 27.8 (27.6) 0.31 CVD Events HR (CI) HR (CI) HR (CI) HR (CI) Model 1 1.08 (0.75, 1.57) 0.67 1.34 (1.08, 1.65) 0.007 1.09 (0.57, 2.08) 0.80 0.99 (0.71, 1.39) 0.97 Model 2 1.10 (0.76, 1.58) 0.61 1.30 (1.05, 1.62) 0.017 0.82 (0.38, 1.78) 0.62 1.00 (0.71, 1.43) 0.98 Model 1 = age and sex ; Model 2 = age, sex, BMI, smoking status, LDL, HDL, triglycerides, hypertension, diabetes
Abstract MP030: Insufficient Sleep Increases Caloric Intake but not Energy Expenditure
Levine, James A. , Calvin, Andrew D. , Carter, Rickey E. , Somers, Virend K.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.amp030 Get It

Introduction: Identifying and mitigating factors that promote obesity will have a large public health impact. Sleep may be an important regulator of metabolism and energy expenditure. Voluntary sleep restriction is common, with 27% of US adults regularly getting ≤6 h of sleep per day. Epidemiologic evidence suggests a link between short sleep duration and obesity. Human experiments suggest that acute sleep deprivation reduces the anorexigenic hormone leptin, increases the orexigenic factor ghrelin, and promotes caloric intake. Meanwhile, increased energy expenditure during prolonged wakefulness may counterbalance any increased caloric intake associated with a lack of sleep. Hypothesis: We hypothesized that 8 days of modest sleep restriction would reduce leptin, increase ghrelin, promote caloric intake, and increase activity energy expenditure. Methods: We studied 17 healthy individuals age 18–40 y. Subjects completed a protocol consisting of one week of home actigraphy, a 3 night acclimation phase, followed by an 8 night experimental phase in which they were randomized to sleep ad lib or two-thirds of their normal sleep time. Blood was collected at the end of the two periods, food was freely available and caloric intake was calculated daily, and activity energy expenditure was assessed by a comprehensively validated system comprised of inclinometers and accelerometers. Sleep was confirmed using continuous electroencephalography. Mean change from the acclimation period ± standard deviation are presented, with statistical testing by two sample t tests on the changes between acclimation and experimental periods. Results: Subjects included 11 men and 6 women, of whom 8 were randomized to sleep deprivation and 9 served as controls. Sleep duration during the acclimation period averaged 6.5±0.9 h/day but fell to 5.2±0.1 h/d among those randomized to sleep deprivation. The sleep deprivation group consumed +549±583 kcal/d, whereas those randomized to ad lib sleep consumed −143±420 kcal/d (P<0.01). Activity energy expenditure by did not change in either group (+1.2±33.0% vs +8.4±34.0%, P=0.68). Sleep deprivation was associated with a trend towards increased leptin (+8.4±4.7% versus −9.8±13.5%, P=0.12) and decreased ghrelin (−4.9±5.3% vs +4.6±7.0%, P=0.38). Conclusions: Eight days of modest sleep restriction, similar to that encountered in everyday life, was associated with a striking increase in caloric intake with no change in activity energy expenditure. Contrary to expectations, we observed a trend towards increased circulating concentrations of leptin and reduced concentrations of ghrelin, more consistent with a consequence of a positive energy balance than a cause. Our data suggest that chronic sleep restriction may be an important and modifiable behavior promoting obesity.
Abstract MP020: Long-term, Visit-to-visit Blood Pressure Variability and the Risk of Total Mortality, MI, and Stroke in the Cardiovascular Health Study
Suchy‐Dicey, Astrid M. , Wallace, Erin R. , Elkind, Mitchell S, Aguilar, Maria I. , Gottesman, Rebecca, Voorman, Arend, Longstreth, W.T. , Rice, Kenneth , Kronmal, Richard A. , Psaty, Bruce M.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.amp020 Get It

Introduction: Recent reports have linked visit-to-visit blood pressure (BP) variability to risk of mortality and stroke, independent of the effect of mean BP level. We sought to confirm these findings in the Cardiovascular Health Study (CHS), a cohort study of cardiovascular risk factors. Hypothesis: Variability in visit-to-visit SBP, defined as intraindividual SBP SD, is directly associated with risk of mortality, myocardial infarction (MI), and stroke, independent of intraindividual SBP mean and trend over time. Methods: Participants from CHS were eligible if they attended their first five annual clinic visits and did not have stroke, MI, or death by the 5th visit (N=3513). Follow-up started at the 5th visit and extended through June 2008. Analyses were further restricted to subjects who used no antihypertensive medications during the entire 5-year baseline period (non-users, n=1570) and subjects who used the same antihypertensive regimen during that time (users, n=978). Intraindividual SBP variables were defined using each subject’s 5-visit BPs. Cox proportional hazards models estimated adjusted hazard ratios (HR) per standard deviation (SD) increase in intraindividual SD (iSD) SBP or intraindividual mean (iMean) SBP. Results were stratified on medication use or non-use. Results: Participants’ mean age was 71 years, 42% were men, and 95% were white. Mean(SD) of iSD SBP was 9.8(4.6) mmHg for anti-hypertensive medications non-users and 12.0(6.0) mmHg for users. iMean SBP was significantly associated with all 3 outcomes among non-users and with stroke among users (table). iSD SBP was significantly associated with mortality in all participants and with MI among non-users; associations for stroke were not significant. Conclusion: Long-term visit-to-visit SBP variability may be an important determinant of MI and mortality risk in the elderly. Results for stroke are not consistent with other, previous reports. More research is needed to determine the clinical implications.
Abstract 19746: Identification of Novel microRNA Profiles in Patients With Myxomatous Mitral Valve Disease
Hagler, Michael A , Thalji, Nassir M , Russell, Nate, Welge, Michael , Bushell, Colleen , Berry, Matthew, White, Bryan A. , Suri, Rakesh M. , Russell, Nate, Berry, Matthew, Miller, Jordan D.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.19746 Get It

Introduction: Myxomatous mitral valve disease (MMVD) is a degenerative condition characterized by tissue fibrosis and matrix remodeling which ultimately progresses to leaflet prolapse. While recent work has shown that transforming growth factor beta (TGF-β) signaling contributes to the pathogenesis of MMVD, upstream regulators of this and other pathways remain poorly understood. Hypothesis: We sought to use high-throughput RNA sequencing coupled with microRNA (miRNA) sequencing to identify novel molecular targets as well as upstream regulators contributing to MMVD. Methods: We conducted mRNA and miRNA sequencing on normal (n = 10) and myxomatous human mitral valve samples (n = 10). Differential expression was identified using linear modeling and parallel random forest analyses. Canonical pathways were identified by Ingenuity Pathway Analyses (IPA). Predicted miRNA targets were identified using TargetScanHuman 6.2. Results: We found 2784 mRNAs that were differentially expressed between normal and myxomatous mitral valves, which IPA largely categorized in to pro-fibrotic, matrix remodeling and cellular proliferation signaling. In miRNA sequenced from the same samples, 67 miRNAs were differentially-expressed between normal and myxomatous mitral valves. Increased expression of TGF-β ligands, collagen isoforms, and matrix metalloproteinases were associated with reductions in miRNAs predicted to target them. Conversely, mRNA levels of the “protective” genes TGFβ-induced factor homeobox 1, salt-inducible kinase 1, TIMP metallopeptidase inhibitor 4, and cyclin-dependent kinase inhibitor 1C mRNA levels were decreased in myxomatous tissue, and miRNAs predicted to target these genes (e.g., miR-656, miR-379-3p, miR-664a-3p, and miR-34c-5p) were significantly increased. Conclusions: Collectively, these data not only identify novel genes that are differentially regulated in MMVD, but also suggest miRNAs may play an active role in suppressing key protective molecules in MMVD. Thus, anti-mIRs therapy may be a viable therapeutic target to restore anti-fibrotic and anti-proliferative molecules in the valve and slow progression of MMVD. Future mechanistic studies will lay a critical foundation for translational work in these areas.
Abstract 19671: Contemporary Patterns of Utilization and Safety Outcomes of Catheter Ablation of Atrial Flutter in the United States
Patel, Nileshkumar , Badheka, Apurva O., Deshmukh, Abhishek , Viles-González, Juan F., Pau, Dhaval

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.19671 Get It

Introduction: Atrial flutter ablation has been increasingly offered as first line therapy and has been safely performed over the past few decades. However, limited data exists regarding current utilization and trends in adverse outcomes arising from this procedure. The aim of our study was to examine the frequency of adverse events attributable to atrial flutter (AFL) ablation and the influence of hospital volume on safety outcomes. Hypothesis: We hypothesize an association between hospital volume and adverse outcomes. Methods: With the use of the Nationwide Inpatient Sample, we identified 89,638 AFL patients treated with catheter ablation from 2000-2011. We investigated common complications including cardiac perforation and tamponade, pneumothorax, stroke, transient ischemic attack, vascular access complications, and in-hospital death. We defined these complications by using validated International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. Results: The overall frequency of complications was 3.17%, with combined cardiac complications (1.44%) being the most frequent. Cardiac complications were followed by vascular complications (0.78%), respiratory complications (0.88%), and neurological complications (0.05%). The in-hospital mortality was 0.17%. Low hospital volume (<50 procedures) was significantly associated with increased adverse outcomes. In addition, there was a small, insignificant rise in overall complication rates over time. Conclusions: The overall complication rate was 3.17% in patients undergoing AFL ablation. There was a significant association between low hospital volume and increased adverse outcomes. This suggests a need for future research into identifying the safety measures in AFL ablations and instituting appropriate interventions to improve overall AFL ablation outcomes.